NCT03810651 Pencil Beam Scanning in Patients With Renal Tumors
| NCT ID | NCT03810651 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Children's Hospital of Philadelphia |
| Condition | Renal Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 28 participants |
| Start Date | 2017-12-26 |
| Primary Completion | 2027-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 28 participants in total. It began in 2017-12-26 with a primary completion date of 2027-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study to assess acute toxicity in patients receiving flank irradiation using proton therapy for renal tumors.
Eligibility Criteria
Inclusion Criteria: * Less than 30 years of age * Diagnosis a. Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care including 1. Any patient with favorable histology (FH), stage III disease 2. Any patient with focal or diffuse anaplasia 3. Any patient with CCSK * The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK Exclusion Criteria: * Prior radiotherapy to the region of the study cancer * Chemotherapy administered for diagnosis of Wilms tumor or CCSK * Pregnant or breastfeeding
Contact & Investigator
Christine Hill-Kayser, MD
PRINCIPAL INVESTIGATOR
Children's Hospital of Philadelphia
Frequently Asked Questions
Who can join the NCT03810651 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 30 Years, studying Renal Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT03810651 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT03810651 currently recruiting?
Yes, NCT03810651 is actively recruiting participants. Contact the research team at hill@uphs.upenn.edu for enrollment information.
Where is the NCT03810651 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT03810651 clinical trial?
NCT03810651 is sponsored by Children's Hospital of Philadelphia. The principal investigator is Christine Hill-Kayser, MD at Children's Hospital of Philadelphia. The trial plans to enroll 28 participants.